Women with metastatic breast cancer have an incurable disease with a median survival of only 2 years after diagnosis of metastatic involvement. have shown a positive correlation between increasing dose median follow-up of 62 months (range 1-109 months), median survival from reinfusion was 16 months with intensity and improved response rates in metastatic breast cancer with numerous attempts made to increase singlea 5-year survival of 19 ؎ 4%. The median event-free survival (EFS) was 8 months with a 5-year EFS of dose intensity by administering combinations of agents in high doses over a short period of time. Initially, harvested 11 ؎ 3%. Patients achieving a complete response to induction therapy showed a higher 5-year EFS from bone marrow was utilized as a source of hematopoietic progenitor cells after high-dose chemotherapy but peripheral reinfusion of 31 ؎ 8% in contrast to 3 ؎ 3% (P = 0.006) for patients who achieved a partial response to inducblood stem cells (PBSC), either alone or in combination with marrow, have now replaced autologous marrow as tion therapy prior to HDC. Marrow involvement or source of stem cell rescue did not affect outcome. Our more rapid engraftment is seen with PBSC.
Summary:
Women with metastatic breast cancer have an incurable disease with a median survival of only 2 years after diagnosis of metastatic involvement.
2,3 Such patients frequently One hundred women with metastatic breast cancer (MBC) underwent high-dose chemotherapy with autoobtain partial disease shrinkage with conventional-dose chemotherapy but complete responses are infrequent. Highlogous stem cell rescue at our institution beginning in 1986. The patients underwent induction chemotherapy dose chemotherapy with autologous peripheral stem cell rescue allows single high-dose intensive chemotherapy from June 1986 to December 1993. Patients who showed stable or responsive disease underwent HDC with cyclotreatment and has been beneficial for certain patients with breast cancer. Data have demonstrated that high-dose phosphamide (CY) at 7.5 g/m 2 and thiotepa (TPA) at 675 mg/m 2 or the same doses of CY and TPA with carchemotherapy is able to convert a substantial number of patients with partial remission to conventional-dose therapy mustine at 450 mg/m 2 . The source of stem cell rescue was either BM alone, BM and G-CSF-mobilized periphto a complete remission after high-dose chemotherapy, and that a number of these patients can remain continuously eral blood progenitor cells (PBPC) or PBPC alone if patients had BM involvement with MBC. With a disease-free for extended periods of time. [4] [5] [6] [7] Hryniuk et al 8, 9 have shown a positive correlation between increasing dose median follow-up of 62 months (range 1-109 months), median survival from reinfusion was 16 months with intensity and improved response rates in metastatic breast cancer with numerous attempts made to increase singlea 5-year survival of 19 ؎ 4%. The median event-free survival (EFS) was 8 months with a 5-year EFS of dose intensity by administering combinations of agents in high doses over a short period of time. Initially, harvested 11 ؎ 3%. Patients achieving a complete response to induction therapy showed a higher 5-year EFS from bone marrow was utilized as a source of hematopoietic progenitor cells after high-dose chemotherapy but peripheral reinfusion of 31 ؎ 8% in contrast to 3 ؎ 3% (P = 0.006) for patients who achieved a partial response to inducblood stem cells (PBSC), either alone or in combination with marrow, have now replaced autologous marrow as tion therapy prior to HDC. Marrow involvement or source of stem cell rescue did not affect outcome. Our more rapid engraftment is seen with PBSC.
10,11
This report is a follow-up 12,13 of our experience in 100 mature results confirm that high-dose chemotherapy with autologous stem cell rescue can confer a prolonged women with metastatic breast cancer who underwent initial induction chemotherapy followed by high-dose chemo-DFS in a subset of women with MBC. However, the high rate of relapse remains a universally disturbing probtherapy and autologous bone marrow and/or peripheral blood stem cell rescue from 1 June 1986 to 31 December lem in this patient population. Keywords: breast cancer; high-dose chemotherapy; bone 1993. Patients who achieved a complete response, partial response or stable disease with induction therapy proceeded marrow transplantation; cyclophosphamide; thiotepa; carmustine to receive consolidation with high-dose chemotherapy and autologous stem cell rescue. This report describes our results in terms of survival, event-free survival, effect of bone marrow involvement at the time of transplant and the Breast cancer is the most common malignant neoplasm in impact of the response to induction therapy on long-term women and is the second leading cause of cancer-related outcome. death in women in the United States. In 1995, it was estimated that 182 000 new cases of breast cancer would be diagnosed with 46 000 women dying of their disease. 
Patients and methods
Because of the high incidence of breast cancer, even small improvements in the efficacy of treatment can potentially
Patient characteristics save thousands of lives annually.
One hundred women with untreated stage IV or metastatic breast cancer underwent one of three different induction 128 size of a measurable lesion or lesions based on the sum of the products of the greatest tumor diameter and its perpenStatistical analysis dicular. Stable disease (SD) was defined as no change in Event-free survival and overall survival as measured from measurable or evaluable disease and no evidence of new the day of autologous stem cell reinfusion were calculated lesions. For patients with bone metastases only, PR was by the method of Kaplan and Meier. 16 Events were condefined as sclerosis in the affected sites without new lesions sidered to be disease progression or death due to any cause. identified upon reevaluation, and CR was defined by comSurvival curves were compared by the log rank test. 17 All plete resolution of osseous metastases by bone scan and tests were two-sided with significance set at 0.05. plain radiographs.
Responding patients then proceeded to high-dose chemoResults therapy with either cyclophosphamide (7.5 g/m 2 ) and thiotepa (675 mg/m 2 ) in 77 women or the same doses of The median age for the 100 patients who underwent highcyclophosphamide and thiotepa with carmustine (BCNU) dose chemotherapy was 43 years (range 20-63 years). The at 450 mg/m 2 in 23 women. majority of patients (64%) had two or more sites of metaApproximately 48-72 h after the high-dose chemostatic involvement and 72% or 72 patients had prior adjutherapy, autologous cryopreserved stem cells were thawed vant chemotherapy. Other patient characteristics are shown and reinfused. The source of stem cell rescue was (1) bone in Table 1 . marrow (44%) or (2) a combination of bone marrow and G-CSF-mobilized peripheral blood progenitors (PBPC) in Antitumor response and survival patients with marrow histologically negative for contami-
The overall complete response rate to induction therapy and nating breast cancer cells (21%) or (3) PBPC alone in high-dose chemotherapy with ABMT was 37%. With a patients who had evidence of breast carcinoma on routine median follow-up duration of 62 months (range 1-109 histopathologic examination of bone core biopsies (35%). months), the median survival from the day of reinfusion The PBPC were obtained after mobilization with cyclopho-(day 0) was 16 months with a 5-year survival rate of sphamide (4 g/m 2 ) alone or cyclophosphamide plus G-CSF.
19 Ϯ 4% (Figure 1 ). The median event-free survival (EFS) The procurement procedure and cryopreservation techniques have been previously described.
12-14
For supportive care, patients were placed in protective isolation and low-bacteria diets. Neutropenic fevers were treated with broad-spectrum antibiotics. Red cell transfusions were performed for hematocrits р25% and prophylactic platelet transfusions were given for a count р20 000 × 10 9 /l. Actively bleeding patients were transfused to maintain a platelet count у50 000 × 10 9 /l. All blood products were irradiated and filtered and CMV-negative blood products were obtained for CMV-negative patients. All patients received prophylactic acyclovir to prevent herpetic infections. After 1991, patients received hematopoietic cytokine support with either GM-CSF or G-CSF beginning granulocyte recovery was complete. Patients with initial tation. One patient who showed SD after induction therapy converted to a CR after high-dose chemotherapy.
Influence of marrow status and stem cell rescue
Thirty-five percent of patients (n = 35) had histologic evidence of marrow metastases on routine tissue sections prior to induction chemotherapy. These patients received mobilized PBPC alone as the source of their stem cell rescue. The remaining patients had no evidence of marrow involvement; 44% received autologous marrow alone and 21% received both autologous marrow and PBPC. There was no duct did not significantly impact upon survival as measured by EFS (Figure 4 ). Ninety percent of the patients with marfrom reinfusion was 8 months with a 5-year EFS rate of row involvement relapsed in sites of previous disease. 11 Ϯ 3% (Figure 1) . For the 38 patients with a complete response after the entire program of induction plus highPatterns of recurrence dose consolidation, the median EFS from reinfusion was 13.7 months with a 5-year EFS rate of 26 Ϯ 7%.
Twenty-five patients relapsed after obtaining a complete Outcome was further analyzed based upon response to response. Sixty-one percent of the relapses were at sites induction therapy; patients achieving CR were compared to those achieving PR. After induction therapy, two patients with bone metastases only experienced a CR, two patients showed a PR and one patient demonstrated SD prior to transplantation.
For the 28 patients in CR prior to high-dose chemotherapy, the median EFS from reinfusion was 12 months vs 6 months for the 42 patients in PR (P = 0.006). The 5-year EFS rate was 31 Ϯ 8% vs 3 Ϯ 3% (P = 0.006), respectively (Figure 2) . Nine of the 42 patients (24%) who achieved PR after induction chemotherapy converted to CR after high-dose consolidation.
Nineteen patients remain alive with 10 of these patients being disease-free (see Table 2 ). The longest complete response duration to date among this group is 7.8 years. Of two patients converting from PR to CR after transplan- In a large retrospective study from MD Anderson Cancer Center on 1581 patients with metastatic breast cancer who received conventional chemotherapy only, achievement of CR was also found to be an important prerequisite in maintaining long-term disease-free status. 21 Seventeen percent of the patients obtained CR with conventional chemotherapy with 3.1% remaining in CR for more than 5 years. The group of patients who achieved long-term CR were younger, premenopausal, had lower tumor burdens and a good performance status. Surprisingly, 59% of the patients in the long-term DFS group had visceral involvement which is a poor prognostic factor in most studies. Of our 10 surviving disease-free patients, six had bone or bone marrow metastases only while four had visceral metastases. Using conventional chemotherapy, several studies have demonstrated the favorable prognosis associated with boneof prior disease. One patient developed acute lymphocytic leukemia (CALLA+, hyperdiploid karyotype) 3 years postonly metastatic disease with this subset of patients tending to follow an indolent, chronic course with prolonged surconsolidation while in CR from breast cancer. Her karyotype had not been previously evaluated prior to the vival. Women with skeletal metastases only were reported to have median survivals over twice as long as patients with diagnosis of acute leukemia. She underwent remission induction therapy and allogeneic bone marrow transplanvisceral metastases. [22] [23] [24] Thus, among our six long-term survivors with bone-only disease, intrinsic biologic factors of tation after relapse but died of transplant-related complications with no evidence of breast cancer at autopsy. Four the disease and not necessarily the aggressive treatment may have contributed to their survival superiority. patients developed new, isolated central nervous system recurrences within 1 year of high-dose therapy and expired Unfortunately, recurrent disease remains a daunting problem with a majority of relapses in areas of prior bulk as a result of these recurrences.
disease, as was seen in our study. These relapse patterns strongly suggest that minimal residual disease may not have been eradicated with the preparative regimen. One attempt Discussion to improve upon this relapse rate is to administer sequential cycles of high-dose chemotherapy over a short duration. Over the past 10 years, high-dose chemotherapy with autologous stem cell rescue has been widely used to treat Potential benefits of this method include maximizing dose intensity, inducing into cycle the cells that were previously women with metastatic breast cancer. It allows high singledose intensity and has been beneficial for certain patients dormant during prior therapy and improving drug delivery by a reduction of bulk disease with the first cycle. 25 Howwith breast cancer.
4,11 The mortality associated with this treatment has been reduced to approximately 1% with the ever, studies that incorporated tandem cycles of high-dose chemotherapy have not convincingly proved that additional advent of hematopoietic growth factors, the replacement of bone marrow with peripheral blood stem cells spurring cycles are beneficial. 26, 27 There are also data suggesting that reinfused malignant more rapid hematopoietic engraftment and improved supportive care. 18 cells can contribute to relapse in some patients. Although there appears to be a reduced risk of tumor cell contamiIn the treatment of metastatic breast cancer, a large amount of data demonstrate that high-dose chemotherapy nation with peripheral blood progenitor cell collections as compared to autologous bone marrow, 28 preliminary trials results in a significantly higher rate of complete remissions as compared to conventional chemotherapy, with the that inserted genetic markers into the autograft (as well as any contaminating tumor cells) suggested that reinfused achievement of a complete response appearing to be a strong predictor for improved survival.
5,7,13 High-dose malignant cells can contribute to relapse in some patients with solid tumors. 29 Our data did not show a significant chemotherapy results in complete remission rates of 25-64% with a median time to progression ranging from 8 to difference in EFS among our subsets of patients classified by source of stem cell rescue but the number of patients in 19 months. 6, 7, 19, 20 Our results in 100 women demonstrated a CR rate of 37% and a 5-year overall survival of 19% each subgroup was small. Ongoing studies aimed at reducing this risk include techniques such as CD34 + selection, with a median EFS of 8 months for all patients.
When the impact of response to induction therapy was ex vivo expansion and in vitro immunomagnetic purging with monoclonal antibodies. [30] [31] [32] analyzed, patients achieving CR prior to high-dose chemotherapy experienced a longer median EFS of 12 months vs Although the histologic presence of bone marrow involvement at the time of transplant did not adversely 6 months and a higher 5-year EFS rate of 33% vs 3%, P = 0.006 as compared to patients who had achieved only a affect EFS in our study, recent reports have shown that the presence of breast cancer in the bone marrow or peripheral PR or SD prior to high-dose chemotherapy, respectively. Thus, the patients with maximally chemosensitive disease blood predict for a poor outcome when either utilizing PCR methods or routine histology. A recent report presented who proceeded to high-dose chemotherapy with minimal tumor bulk appeared to reap the most benefit in terms of compelling data that demonstrated a strong correlation between the incidence of marrow involvement and the prolonged EFS.
probability of relapse when PCR methods were employed extend those reported by others, confirming that there is a subset of women treated with high dose chemotherapy and to detect metastases. 33 Fields et al used PCR methods to retrospectively analyze the cryopreserved samples of bone ABMT who enjoy prolonged disease-free survival. However, the disturbing rate of relapse in this patient population marrow that were histologically negative in 83 stage IV breast cancer patients who subsequently underwent highremains a universal problem. Hopefully, ongoing trials utilizing immunomodulatory cytokines and growth factors dose chemotherapy with autologous bone marrrow rescue. An 82% incidence of occult marrow metastases was discopost-transplant will positively impact upon recurrent disease and subsequently lead to prolonged survival. vered. Their study found that the 3-year probability of relapse was markedly increased in patients with PCR+ marrow as compared to patients with PCRϪ marrow (92% vs References 14%, P = 0.0002). Based on these data, the 63% of our patients who had histologically negative bone marrow is static breast cancer was recently reported. 20 Bezwoda et al 34 weeks in the conventionally treated patients and median
